Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI) (PRECISE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01275092
Recruitment Status : Completed
First Posted : January 12, 2011
Results First Posted : August 8, 2013
Last Update Posted : August 8, 2013
Sponsor:
Information provided by (Responsible Party):
Corindus Inc.

Tracking Information
First Submitted Date  ICMJE January 7, 2011
First Posted Date  ICMJE January 12, 2011
Results First Submitted Date  ICMJE August 9, 2012
Results First Posted Date  ICMJE August 8, 2013
Last Update Posted Date August 8, 2013
Study Start Date  ICMJE January 2011
Actual Primary Completion Date December 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 6, 2013)
  • Percentage of Participants With Clinical Procedural Success [ Time Frame: 48-hrs or hospital discharge, whichever occurs first ]
    Defined as <30% residual stenosis in CorPath 200 System treated lesions at the completion of the interventional procedure (including stent placement) in the absence of MACE, either within 48 hours of the procedure or prior to hospital discharge, whichever occurs first.
  • Percentage of Patients With Device Technical Success [ Time Frame: 1 day ]
    Defined as the successful advancement and retraction of PCI devices using the CorPath 200 System and without conversion to manual operation.
Original Primary Outcome Measures  ICMJE
 (submitted: January 10, 2011)
  • Clinical Procedural Success [ Time Frame: 48-hrs or hospital discharge, whichever occurs first ]
    Defined as <30% residual stenosis in CorPath 200 System treated lesions at the completion of the interventional procedure (including stent placement) in the absence of MACE, either within 48 hours of the procedure or prior to hospital discharge, whichever occurs first.
  • Device Technical Success [ Time Frame: 1 day ]
    Defined as the successful advancement and retraction of PCI devices using the CorPath 200 System and without conversion to manual operation.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 6, 2013)
The Ratio Between the Radiation Exposure of the Primary Operator and the Radiation Exposure at the Table [ Time Frame: 1 day ]
Defined as the difference between the radiation exposure measured at the procedure table (the conventional site of the primary operator) and the radiation exposure measured at the primary operator's position during the procedure. The radiation unit that was used was in milligray, but the measure is being reported as the ratio.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 10, 2011)
Reduction in Primary Operator Radiation Exposure [ Time Frame: 1 day ]
Defined as the difference between the radiation exposure measured at the procedure table (the conventional site of the primary operator) and the radiation exposure measured at the primary operator's position during the procedure.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
Official Title  ICMJE CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Brief Summary The objective of this study is to evaluate the safety and effectiveness of the clinical and technical performance of the CorPath® 200 System in the delivery and manipulation of coronary guidewires and stent/balloon systems for use in percutaneous coronary interventions (PCI).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Coronary Artery Disease
  • Coronary Disease
  • Myocardial Ischemia
  • Heart Diseases
  • Cardiovascular Diseases
  • Arteriosclerosis
  • Arterial Occlusive Diseases
  • Vascular Diseases
Intervention  ICMJE Device: CorPath robotic-assisted PCI
CorPath 200® robotic-assisted percutaneous coronary intervention
Study Arms  ICMJE Experimental: CorPath robotic-assisted PCI
CorPath 200 robotic-assisted PCI
Intervention: Device: CorPath robotic-assisted PCI
Publications * Weisz G, Metzger DC, Caputo RP, Delgado JA, Marshall JJ, Vetrovec GW, Reisman M, Waksman R, Granada JF, Novack V, Moses JW, Carrozza JP. Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study. J Am Coll Cardiol. 2013 Apr 16;61(15):1596-600. doi: 10.1016/j.jacc.2012.12.045.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 6, 2013)
164
Original Estimated Enrollment  ICMJE
 (submitted: January 10, 2011)
175
Actual Study Completion Date  ICMJE January 2012
Actual Primary Completion Date December 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

General Inclusion Criteria:

  1. Subject is between 18 and 99 years of age.
  2. Subject is an acceptable candidate for PCI.
  3. Subject must have clinical evidence of ischemic heart disease or a positive functional study.
  4. Female subjects must be of non-child bearing potential, or if able to bear children, have a negative pregnancy test within 7 days prior to the CorPath procedure.
  5. The subject or the legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.

Angiographic Inclusion Criteria:

  1. Study lesion is a single de novo native coronary artery lesion. This lesion may consist of multiple lesions (with 10mm or less between diseased segments) and must be completely covered by a single stent with at least 2.0mm of normal segments on proximal and distal edges of the lesion.
  2. Study reference vessel diameter is between 2.5mm and 4.0mm by visual estimate.
  3. Study lesion length is less than or equal to 24.0mm by visual estimate.
  4. Study lesion diameter showing stenosis of at least 50% by visual estimate.

General Exclusion Criteria:

  1. Subject requires planned PCI or CABG (Coronary Artery Bypass Graft) within 30 days following the CorPath procedure.
  2. Evidence of an acute myocardial infarction within 72 hours prior to the intended CorPath procedure.
  3. Subject has documented left ventricular ejection fraction <30%.
  4. Subject has undergone PCI within 72 hours prior to the CorPath procedure.
  5. Subject has undergone PCI within 30 days prior to the CorPath procedure and experienced a major adverse coronary event (MACE) or a serious adverse event (SAE) as defined in the protocol.
  6. Subject has known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, prasugrel, stainless steel, cobalt chromium, or sensitivity to contrast media, including Visipaque™, which cannot be adequately pre-medicated or managed with clinically appropriate substitutes.
  7. Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, or a WBC (white blood cell) count of <3,000 cells/mm3 (e.g. thrombocytopenia, thrombocythemia, neutropenia or leukopenia).
  8. Subject has a serum creatinine level of >2.0 mg/dL or eGFR (estimated Glomerular Filtration Rate) <30 ml/min as measured within 7 days prior to the procedure.
  9. Subject has suffered a stroke within 30 days prior to planned CorPath procedure.
  10. Subject has an active peptic ulcer or upper gastrointestinal bleeding within the 6 months prior to planned CorPath procedure.
  11. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  12. Subject is currently participating in another investigational drug or drug/device or device trial and has not completed the entire follow up period.
  13. Femoral access is not possible.

Angiographic Exclusion Criteria:

  1. Target lesion that cannot be fully covered by a single stent.
  2. Subject requires treatment of more than one vessel.
  3. Any previous stent placement within 5.0 mm (proximal or distal) of the target lesion.
  4. The study lesion requires planned treatment with directional coronary atherectomy (DCA), laser, rotational atherectomy or any device except for balloon dilatation prior to stent placement.
  5. The study vessel has evidence of intraluminal thrombus.
  6. The study vessel has evidence of moderate to severe tortuosity (>90°) proximal to the target lesion.
  7. The study lesion has any of the following characteristics:

    • Total occlusion.
    • Ostial location.
    • Is within 2.0 mm of a side branch measuring >2.0 mm in diameter.
    • Located at < 45° bend in the vessel.
    • Moderately to severely calcified.
    • Moderate to severe calcification in the vessel proximal to the target lesion.
    • Located in a native vessel distal to an anastomosis, with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass, and is approached through the bypass graft.
  8. Unprotected left main coronary artery disease defined as an obstruction greater than 50% diameter stenosis in the left main coronary artery.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Colombia,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01275092
Other Study ID Numbers  ICMJE CorPath PRECISE
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Corindus Inc.
Study Sponsor  ICMJE Corindus Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Michail Pankratov, MD/PhD Corindus Inc.
PRS Account Corindus Inc.
Verification Date August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP